ClinicalTrials.gg
TerminatedNCT00634790Updated Jan 28, 2021

A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks

A Phase 4 interventional study of alprazolam XR in Panic Disorder, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 47 sites in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Why this study was terminated
Please see Detailed Description for termination reason.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
49
Allocation
Non-randomized
Ages
13 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 109 studies in Panic Disorder with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Panic Disorder · United States.

Enrollment
60th of 94
49 · median 69
Started
2004
with 8 others
Phase 4
18 of 109
none open now
Registered
40th of 109
by date

Among the 109 studies in Panic Disorder with a site in United States, this one is the 60th largest by enrollment of the 94 interventional ones that give a count, is one of 9 that started in 2004, is one of 18 in phase 4, and was the 40th registered.

Panic Disorder

270 studies on the registry are indexed under Panic Disorder; 37 are open to participants now.

Browse Panic Disorder studies →

Open to participants now

9 of the 109 studies in Panic Disorder with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Panic Disorder studies recruiting now, 8 (33%) set no upper age limit and 15 (63%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 13 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Panic Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the long-term safety and tolerability of alprazolam extended release (XR) in adolescents with panic disorder, with or without agoraphobia, or in anxiety disorder with panic attacks. Efficacy, population pharmacokinetics of alprazolam XR and the relationship between alprazolam XR plasma concentrations and efficacy outcomes will also be evaluated.

Read the detailed description

Due to recruitment difficulties in this adolescent population, the clinical program for alprazolam XR was cancelled and this study was terminated on 1 September 2004. There were no safety concerns that led to this decision.

03

Conditions studied

  • Panic Disorder

Browse trials for

04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must meet one of the following 6 diagnoses: a. A current diagnosis of panic disorder with or without agoraphobia; b. Generalized anxiety disorder with a history of at least one panic attack in the course of their illness; c. Social anxiety disorder (social phobia) with a history of at least one panic attack in the course of their illness; d. Separation anxiety with a history of at least one panic attack in the course of their illness; e. Posttraumatic stress disorder with a history of at least one panic attack in the course of their illness; f. Anxiety not otherwise specified with a history of at least one panic attack in the course of their illness.
  • Educational level, intelligence, or other mental condition in the subject and/or his/her parent(s) are judged by the investigator to be sufficient to permit adequate /assent to be obtained, and for study procedures to be complied with.

Exclusion criteria

Exclusion Criteria:

  • Current (in the past 6 months) diagnosis of obsessive compulsive disorder, major depressive disorder, dysthymic disorder, or alcohol and/or substance dependence.
  • Current (in the past 3 months) diagnosis of alcohol and/or substance abuse.
  • Primary diagnosis of conduct disorder, oppositional defiant disorder, or Attention Deficit Hyperactivity Disorder.
  • Any current or past history of schizophrenia or psychosis; bipolar disorder or cyclothymia; dementia, delirium or other organic brain disease; an eating disorder; mental retardation, Asperger's disorder, or any other serious developmental disorder.
  • A Childhood Depression Rating Scale, Revised score >35.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Active comparator
    alprazolam group

    Drug: alprazolam XR

Interventions

  • Alprazolam XR oral tablet 1 mg daily for 7 days; thereafter the daily dose will be titrated at a maximum rate of 1 mg every 7 days up to a maximum dose of 6 mg; dose adjustments up or down may be made, at a rate not to exceed 1 mg every 7 days; alprazolam XR will be administered for a total of 6 months followed by a gradual taper at a rate of 1 mg every 7 days.

    Also known as: Xanax XR

06

What researchers measure

Primary outcomes

  1. Endpoint change from baseline to Week 24 in Digit Symbol-Coding Test, immediate recall, and delayed recall

    Time frame: 24 weeks

  2. Baseline-to-peak Physician's Withdrawal Checklist change score during 6-week taper off alprazolam

    Time frame: 6 week taper

  3. The incidence of treatment-emergent adverse event during treatment with alprazolam XR

    Time frame: 24 weeks with taper

Secondary outcomes

  1. Descriptive estimates of the persistence of safety events and adverse events at study endpoint

    Time frame: 24 weeks with taper

  2. Endpoint change from baseline to Week 24 in the Panic Disorder Severity Scale-Adolescent version total and item scores

    Time frame: 24 weeks

  3. Endpoint (Week 24) Clinical Global Impression (CGI)-Improvement score

    Time frame: 24 weeks

  4. Endpoint change from baseline to Week 24 in CGI-Severity score

    Time frame: 24 weeks

  5. Endpoint (Week 24) Pediatric Quality of Life, Enjoyment, and Satisfaction Questionnaire improvement score

    Time frame: 24 weeks

07

Study locations

47 sites
  • Pfizer Investigational Site
    Little Rock, Alaska 72223, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85016, United States
  • Pfizer Investigational Site
    Scottsdale, Arizona 85251, United States
  • Pfizer Investigational Site
    Burbank, California 91506, United States
  • Pfizer Investigational Site
    El Centro, California 92243, United States
  • Pfizer Investigational Site
    La Mesa, California 91942, United States
  • Pfizer Investigational Site
    Los Angeles, California 90010, United States
  • Pfizer Investigational Site
    Oceanside, California 92056, United States
  • Pfizer Investigational Site
    San Diego, California 92111, United States
  • Pfizer Investigational Site
    San Marcos, California 92078, United States
  • Pfizer Investigational Site
    Gainesville, Florida 32610, United States
  • Pfizer Investigational Site
    Hialeah, Florida 33013, United States
  • Pfizer Investigational Site
    Jacksonville, Florida 32216, United States
  • Pfizer Investigational Site
    North Miami, Florida 33161, United States
  • Pfizer Investigational Site
    Saint Petersburg, Florida 33710, United States
  • Pfizer Investigational Site
    West Palm Beach, Florida 33409, United States
  • Pfizer Investigational Site
    Decatur, Georgia 30030, United States
  • Pfizer Investigational Site
    Boise, Idaho 83702, United States
  • Pfizer Investigational Site
    Schaumburg, Illinois 60194, United States
  • Pfizer Investigational Site
    Terre Haute, Indiana 47802, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66214, United States
  • Pfizer Investigational Site
    Lexington, Kentucky 40509, United States
  • Pfizer Investigational Site
    Owensboro, Kentucky 42301, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70112, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70114, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21208, United States
  • Pfizer Investigational Site
    Clinton Township, Michigan 48038, United States
  • Pfizer Investigational Site
    Saint Paul, Minnesota 55101, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68131, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada 89102, United States
  • Pfizer Investigational Site
    Clementon, New Jersey 08021, United States
  • Pfizer Investigational Site
    Kenilworth, New Jersey 07033, United States
  • Pfizer Investigational Site
    Morristown, New Jersey 07962, United States
  • Pfizer Investigational Site
    Bismarck, North Dakota 59501, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44106-5080, United States
  • Pfizer Investigational Site
    Lyndhurst, Ohio 44124, United States
  • Pfizer Investigational Site
    Eugene, Oregon 97401, United States
  • Pfizer Investigational Site
    Bala-Cynwyd, Pennsylvania 19004, United States
  • Pfizer Investigational Site
    Hershey, Pennsylvania 17033-0850, United States
  • Pfizer Investigational Site
    Media, Pennsylvania 19063, United States
  • Pfizer Investigational Site
    Columbia, South Carolina 29201, United States
  • Pfizer Investigational Site
    Selmer, Tennessee 38375-1645, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84117, United States
  • Pfizer Investigational Site
    Midlothian, Virginia 23112, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23294, United States
  • Pfizer Investigational Site
    Middleton, Wisconsin 53562, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2004 and a completion of Oct 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2008
First posted
Mar 13, 2008
Start
May 2004
CompletionActual
Oct 2004
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00634790
Responsible party
Sponsor
First posted
Mar 13, 2008
Start date
May 2004
Completion
Oct 2004
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alprazolam

Start the discussion